Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma

BACKGROUND: Activated B cell-like subtype of diffuse large B cell lymphoma (ABC-DLBCL) presents aggressive clinical courses and poor prognosis. Targeting key pathways may raise the possibility of improving clinical outcomes. METHODS: The synergetic effects were assessed by CCK-8 assay and measured b...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Zhen, Qing, Kai, Ouyang, Yuan, Liu, Zhao, Wang, Wenfang, Li, Xiaoyang, Xu, Zizhen, Li, Junmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806505/
https://www.ncbi.nlm.nih.gov/pubmed/27009084
http://dx.doi.org/10.1186/s13046-016-0327-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806505/
https://www.ncbi.nlm.nih.gov/pubmed/27009084
http://dx.doi.org/10.1186/s13046-016-0327-x

Ejemplares similares